James N. Moy, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Induction of tolerance in a patient with a history of exfoliative dermatitis to trimethoprim-sulfamethoxazole.
   Rabbat JC, Lin MY, Moy JN.
   Ann Allergy Asthma Immunol. 2012
   2012 Nov
   109(5):360-1. doi: 10.1016/j.anai.2012.08.001. Epub 2012 Aug 22. No abstract available.
   
2. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
   Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM.
   J Clin Immunol. 2012
   2012 Aug
   32(4):663-9. doi: 10.1007/s10875-012-9656-5. Epub 2012 Mar 6.
   
3. This letter was referred to the authors of the article in question for a response.
   Moy JN, Patel UO, Fox SR, Korbet SM.
   Semin Dial.
   2011 Nov
   24(6):687 doi: 10.1111/j.1525-139X.2011.01013.x
   
4. Pruritic rash and eosinophilia in a patient receiving peritoneal dialysis.
   Patel UO, Fox SR, Moy JN, Korbet SM.
   Semin Dial.
   2011 May-Jun
   24(3):338-40. doi: 10.1111/j.1525-139X.2011.00937.x.
   
5. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.
   Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA, Machnig T, Keinecke HO, Wasserman RL.
   Allergy. 2011
   2011 Dec
   66(12):1604-11. doi: 10.1111/j.1398-9995.2011.02702.x. Epub 2011 Sep 2.
   
6. Tobacco exposure and asthma morbidity in Puerto Ricans and Mexican Americans.
   Martin MA, Sadowski LS, Moy JN, Kumar R.
   Ann Allergy Asthma Immunol.
   2011 Apr
   106(4):346-8
   
7. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency
   Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, Ochs H, Stein M
   J Clin Immunol
   2010 Mar
   30(2):321-9
   
8. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases
   Moy JN, Scharenberg AM, Stein MR, Suez D, Roberts RL, Levy RJ, Ballow M, Fasano MB, Dash CH, Leach SJ
   Clin Exp Immunol
   2010 Dec
   162(3):510-5; doi: 10.1111/j.1365-2249.2010.04247.x
   
9. A community-based study of tobacco smoke exposure among inner-city children with asthma in Chicago
   Kumar R, Curtis LM, Khiani S, Moy J, Shalowitz MU, Sharp L, Durazo-Arvizu RA, Shannon JJ, Weiss KB
   J Allergy Clin Immunol
   2008 Oct
   122(4):754-759. e1